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Background {#sec1}
==========

The outcomes of patients infected with respiratory viruses prior to allogeneic hematopoietic cell transplantation (HCT) are largely unknown. We sought to determine whether respiratory virus detection before HCT influenced overall survival, days hospitalized, and incidence of bronchoscopy during the first 100 days after HCT.

Methods {#sec2}
=======

Pre-HCT and weekly post-HCT nasal washes were collected from patients through day 100 between 12/2005 and 04/2010. Nasal and bronchoalveolar lavage samples, if available, were tested by PCR for respiratory syncytial virus (RSV), parainfluenza virus (PIV) types 1-4, influenza A & B (Flu), metapneumovirus (MPV), adenovirus (AdV), rhinoviruses (RHV), coronaviruses (CoV), and bocavirus (BoV). We analyzed outcomes between patients with and without pre-transplant infections. We defined viruses associated with less severe respiratory disease (RHV, CoV, BoV) as Group 1, and those with more severe disease (RSV, PIV, Flu, MPV, AdV) as Group 2. Hospitalization was analyzed as number of days alive and not hospitalized.

Results {#sec3}
=======

Respiratory viruses were detected in samples between 1 and 60 days (median 17 days) before HCT from 115 (25%) of 453 patients. Those with a respiratory virus detected were younger (p = 0.002) and more likely to have high-risk underlying disease (p = 0.009). In a multivariable model, patients with positive pre-HCT samples had significantly worse survival and averaged nearly 10 fewer days out of the hospital between day 1 and 100 (Table). Group 2 viruses were associated with increased incidence of undergoing bronchoscopy.Table 1Simple and Adjusted Models of Mortality, Hospitalization, and Bronchoscopy Incidence During the First 100 Days After HCT by Pre-transplant Respiratory Virus Status.OutcomeRespiratory VirusUnadjustedAdjusted[∗](#tblfn1){ref-type="table-fn"}HR (95% CI)p-valueHR (95% CI)^1^p-value**Overall survival**No virus (N=338)1.0-1.0-All viruses (N=115)2.1 (1.1 -- 3.7)0.022.0 (1.1 -- 3.8)0.02Group 1 (n=71)2.0 (1.0 -- 4.0)0.051.9 (1.0 -- 4.0)0.07Group 2 (n=44)2.1 (0.9 -- 4.9)0.072.2 (0.9 -- 5.2)0.07**Days (95% CI)p-valueDays (95% CI)^2^p-valueDays alive and out of hospital**No virus (N=338)0-0-All viruses (N=115)-9.8 (-15.3, -4.2)\<0.001-8.7 (-13.9, -3.6)\<0.001Group 1 (n=71)-9.8 (-16.6, -3.1)0.004-8.5 (-14.7, -2.3)0.008Group 2 (n=44)-9.7 (-17.9, -1.4)0.02-9.2 (-16.8, -1.5)0.02**HR (95% CI)p-valueHR (95% CI)^3^p-valueBronchoscopy incidence**No virus (N=338)1.0-1.0-All viruses (N=115)1.6 (1.0 -- 2.5)0.061.4 (0.9 -- 2.2)0.17Group 1 (n=71)1.3 (0.7 -- 2.3)0.431.1 (0.6 -- 2.1)0.69Group 2 (n=44)2.1 (1.1 -- 3.8)0.021.8 (1.0 -- 3.4)0.05[^1]

Conclusion {#sec4}
==========

One in 4 patients was infected with a respiratory virus before HCT. The presence of a pre-HCT respiratory virus infection was associated with increased mortality, prolonged hospitalization, and increased pulmonary morbidity. Unfortunately, delay of HCT is often not feasible and effective treatment is unavailable for most respiratory viruses. These data emphasize the need for intensified prevention of pre-HCT respiratory virus acquisition and improved management strategies, including the development of new antiviral agents.

[^1]: All outcomes adjusted for disease risk. Also adjusted for ^1^age, stem cell source, donor type; ^2^stem cell source, transplant type; and ^3^age.
